Goldman Sachs Group Inc. Has $5.25 Million Stake in Novavax, Inc. $NVAX

Goldman Sachs Group Inc. lowered its holdings in shares of Novavax, Inc. (NASDAQ:NVAX) by 19.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 819,260 shares of the biopharmaceutical company’s stock after selling 197,252 shares during the quarter. Goldman Sachs Group Inc. owned 0.51% of Novavax worth $5,251,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the business. Rhumbline Advisers raised its position in shares of Novavax by 3.3% during the first quarter. Rhumbline Advisers now owns 215,413 shares of the biopharmaceutical company’s stock worth $1,381,000 after purchasing an additional 6,949 shares during the period. Strs Ohio acquired a new stake in shares of Novavax during the first quarter worth about $167,000. Bayforest Capital Ltd bought a new position in shares of Novavax during the first quarter worth about $404,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Novavax by 16.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 312,789 shares of the biopharmaceutical company’s stock worth $2,005,000 after buying an additional 44,105 shares in the last quarter. Finally, Caxton Associates LLP bought a new position in shares of Novavax during the first quarter worth about $158,000. Institutional investors and hedge funds own 53.04% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on NVAX. HC Wainwright began coverage on Novavax in a report on Thursday, August 28th. They set a “buy” rating and a $10.00 price objective for the company. Citigroup began coverage on Novavax in a report on Tuesday, June 17th. They set a “sell” rating and a $6.00 price objective for the company. Finally, Bank of America reiterated an “underperform” rating and set a $7.00 price objective (down from $9.00) on shares of Novavax in a report on Wednesday, August 20th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $14.29.

Novavax Stock Performance

NVAX opened at $8.56 on Wednesday. Novavax, Inc. has a 12-month low of $5.01 and a 12-month high of $15.22. The stock has a market cap of $1.39 billion, a price-to-earnings ratio of 3.75, a PEG ratio of 0.11 and a beta of 2.68. The business has a 50 day moving average of $7.72 and a 200-day moving average of $7.17. The company has a quick ratio of 2.34, a current ratio of 2.36 and a debt-to-equity ratio of 5.93.

Novavax (NASDAQ:NVAX) last released its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.69. The company had revenue of $239.24 million during the quarter, compared to analysts’ expectations of $149.19 million. Novavax had a negative return on equity of 142.33% and a net margin of 39.20%.The business’s revenue was down 42.4% on a year-over-year basis. During the same period last year, the firm posted $0.99 earnings per share. On average, equities research analysts expect that Novavax, Inc. will post -1.46 earnings per share for the current year.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.